Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?

Kristin N. Kelly, Francisco I. Macedo, Nipun B. Merchant

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish (US)
Title of host publicationAdvances in Surgery
EditorsJohn L. Cameron
PublisherAcademic Press Inc.
Pages49-68
Number of pages20
ISBN (Print)9780323755238
DOIs
StatePublished - Sep 2020

Publication series

NameAdvances in Surgery
Volume54
ISSN (Print)0065-3411

Keywords

  • Borderline resectable pancreatic cancer
  • CA 19-9
  • FOLFIRINOX
  • Gemcitabine-abraxane
  • Locally advanced pancreatic cancer
  • Neoadjuvant chemotherapy
  • Portal vein resection
  • Whipple procedure

ASJC Scopus subject areas

  • Surgery

Cite this

Kelly, K. N., Macedo, F. I., & Merchant, N. B. (2020). Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? In J. L. Cameron (Ed.), Advances in Surgery (pp. 49-68). (Advances in Surgery; Vol. 54). Academic Press Inc.. https://doi.org/10.1016/j.yasu.2020.05.001